| Literature DB >> 30574307 |
Magno F Formiga1,2, Isabel Vital3, Gisel Urdaneta3, Kira Balestrini3, Lawrence P Cahalin1, Michael A Campos3,4.
Abstract
OBJECTIVES: The Test of Incremental Respiratory Endurance is a novel testing method that provides a unique examination of one's inspiratory muscle strength, work and endurance. Little is known about the relationship between inspiratory muscle performance and mortality risk in obstructive lung disease. We examined the relationship between the Test of Incremental Respiratory Endurance measures and the Body-mass index, airflow Obstruction, Dyspnea and Exercise index in chronic obstructive pulmonary disease.Entities:
Keywords: Chronic obstructive pulmonary disease; inspiratory muscle performance; mortality risk; test of incremental respiratory endurance
Year: 2018 PMID: 30574307 PMCID: PMC6295678 DOI: 10.1177/2050312118819015
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Figure 1.The Test of Incremental Respiratory Endurance (TIRE) procedure. Subjects received standardized instructions and encouragement to facilitate maximal performance.
Figure 2.Inspiratory muscle strength and endurance assessment template obtained via the PrO2 device.
Descriptive statistics of the study population by BODE index quartiles.
| General group | Quartile I (0–2 points) | Quartile II (3–4 points) | Quartile III (5–6 points) | Quartile IV (7–10 points) | p value | |
|---|---|---|---|---|---|---|
| N (% of total) | 70 (100%) | 15 (21.4%) | 26 (37.1%) | 17 (24.3%) | 12 (17.1%) | |
| Age (years) | 70.2 ± 5.9 | 69.5 ± 4.8 | 69.7 ± 6.1 | 71.1 ± 5.3 | 70.5 ± 8.0 | 0.83 |
| BODE variables | ||||||
| BMI (kg/m2) | 25.7 ± 5.3 | 27.3 ± 4.6 | 25.9 ± 5.6 | 23.2 ± 4.0 | 26.8 ± 7.1 | 0.11 |
| Post-BD FEV1 (L) | 1.5 ± 0.6 | 2.1 ± 0.4 | 1.6 ± 0.5 | 1.4 ± 0.6 | 0.9 ± 0.2 | 0.00 |
| Post-BD FEV1 (% predicted) | 45.3 ± 17.0 | 63.5 ± 11.3 | 46.4 ± 14.2 | 39.2 ± 15.3 | 28.7 ± 7.2 | 0.00 |
| mMRC (0–4) | 1.9 ± 1.2 | 0.9 ± 0.7 | 1.8 ± 1.0 | 2.2 ± 1.3 | 3.4 ± 0.5 | 0.00 |
| 6MWD (m) | 298.2 ± 108.2 | 387.3 ± 58.9 | 318.4 ± 79.7 | 276.7 ± 104.1 | 159.9 ± 81.3 | 0.00 |
| TIRE outcomes | ||||||
| MIP (cmH2O) | 77.8 ± 23.6 | 86.9 ± 23.5 | 80.9 ± 24.7 | 72.5 ± 22.5 | 67.4 ± 19.5 | 0.18 |
| SMIP (PTU) | 405.3 ± 140.0 | 469.7 ± 124.0 | 415.2 ± 148.1 | 409.7 ± 115.8 | 297.2 ± 124.3 | 0.02 |
| ID (s) | 10.0 ± 2.8 | 11.1 ± 2.2 | 10.1 ± 3.1 | 10.0 ± 3.0 | 8.4 ± 2.0 | 0.05 |
GOLD: the Global Initiative for Chronic Obstructive Lung Disease classification; BMI: body mass index; post-BD FEV1: post-bronchodilator forced expiratory volume in the first second; mMRC: modified Medical Research Council dyspnea scale; 6MWD: 6-min walk distance; TIRE: Test of Incremental Respiratory Endurance; MIP: maximal inspiratory pressure; SMIP: sustained maximal inspiratory pressure; ID: inspiratory duration.
Values are expressed as mean ± standard deviation.
p values reflect Kruskal–Wallis comparisons across groups (Quartile I vs II vs III vs IV).
Figure 3.Distribution of MIP, SMIP and ID values across BODE quartiles.
Figure 4.Scatterplots with lines of best fit on the relationships of MIP (left), SMIP (middle) and ID (right) with the BODE score in the study population.